

N-[5-(3-[2,6-Diamino-4(3H)-oxopyrimidin-5-yl)thio]-propyl)-3-methyl-thieno- 2-yl]-L-glutamic acid;

Q/
N-[5-(3-[2,6-Diamino-4(3H)-oxopyrimidin-5-yl)thio]-propyl)-4-methyl-thieno- 2-yl]-L-glutamic acid;

N-6{[([2,6-diamino-4(3H)-oxopyrimidino-5-yl]thio)-methyl]-4,5,6,7-tetrahydrobenzothieno-2-yl}-S-glutamic acid;

N-(5-[2-([2,6-Diamino-4(3H)-oxopyrimidin-5-yl]thio)ethyl]thieno-2-yl)-L-glutamic acid;

N-(4[4-[2-([2,6-Diamino-4(3H)-oxopyrimidin-5-yl]thio)ethyl]benzoyl)-L-glutamic acid; and
the pharmaceutically acceptable salts thereof.

REMARKS

Reconsideration of the above application is respectfully requested.

Claims 52 and 54-61 are pending in the application. Claims 52 and 54-61 have been cancelled without prejudice. Claim 62 has been added. Entry of this amendment is requested. Upon entry of this amendment, claim 62 is pending.

I. Double Patenting Rejection

The Examiner has rejected claims 52 and 54-61 on the grounds of double patenting. Applicants respectfully traverse. Applicants respectfully submit that the Examiner's rejection is rendered moot by deletion of claims 52 and 54-61. Applicants, therefore, respectfully request that the Examiner remove his rejection on these grounds.

II. Claim Rejections Under 35 U.S.C. § 112, Second Paragraph

The Examiner has rejected claims 52 and 54-61 under 35 U.S.C. § 112, second paragraph, on the grounds of indefiniteness. Applicants respectfully traverse. Applicants respectfully submit that the Examiner's rejection is rendered moot by deletion of claims 52 and 54-61. Applicants, therefore, respectfully request that the Examiner remove his rejection on these grounds.